LindevsNiagen Bioscience

LIN and NAGE stock compared: price, dividend, valuation and results, from SEC filings.

Linde (LIN) has a market value of $243B and Niagen Bioscience (NAGE) $161M. Over the last year, with dividends, LIN moved +25.3% and NAGE -70.7%. The P/E is 34.6 for LIN and 15.7 for NAGE. Dividend yield: LIN 1.20%, NAGE none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LIN$243B

    NAGE$161M

    LIN is 1,507 times NAGE

  • Revenue, 12 months

    LIN$36.2B

    NAGE$122M

    LIN is 296 times NAGE

  • Net income, 12 months

    LIN$7.0B

    NAGE$10M

    LIN is 684 times NAGE

  • Operating margin

    LIN25.3%

    NAGE3.9%

    21.4 points apart

  • ROIC

    LIN11.1%

    NAGE5.6%

    5.5 points apart

  • P/E

    LIN34.6

    NAGE15.7

    LIN is 2.2 times NAGE

  • Dividend yield

    LIN1.2%

    NAGE0.0%

    1.2 points apart

  • 5-year return

    LIN+67.7%

    NAGE-67.2%

    134.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LIN+67.7%

NAGE-67.2%

10020020222023202420252026
Returns by period
PeriodLINWith dividendsNAGEWith dividends
1 year since November 14, 2025+25.3%Price +23.6%-70.7%Price -70.7%
3 years since November 16, 2023+33.2%+10.0% a yearPrice +28.2%+37.7%+11.2% a yearPrice +37.7%
5 years since November 15, 2021+67.7%+10.9% a yearPrice +56.7%-67.2%-20.0% a yearPrice -67.2%
10 years since November 17, 2016+431.1%+18.2% a yearPrice +350.1%-23.0%-2.6% a yearPrice -23.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LINLindeNAGENiagen Bioscience

Valuation

LINNAGE
Valuation
Price$523.46$2.01
Market value$243B$161M
Enterprise value (EV)$264B$91M
P/E34.615.7
P/E, 5-year median32.6–
P/B6.21.9
EV/EBIT28.819.2
Free cash flow yield2.1%–

Results and growth

LINNAGE
Results and growth
Revenue, 12 months$36.2B$122M
Net income, 12 months$7.0B$10M
Free cash flow, 12 months$5.1B–
Earnings per share, 12 months$15.06$0.12
Revenue growth, year on year3.0%30.0%
Revenue growth a year, past+4.5%over 5 years+16.9%over 5 years
EPS growth a year, past+25.4%over 5 years–

Margins and returns on capital

LINNAGE
Margins and returns on capital
Gross margin47.9%63.9%
Operating margin25.3%3.9%
Net margin19.3%8.4%
ROIC11.1%5.6%
ROE18.1%13.0%

Balance sheet

LINNAGE
Balance sheet
Cash$3.9B$70M
Total debt$25.2B$2.1M
Net debt / EBITDA1.7-12.9
Interest cover35.5×–

Dividends and buybacks

LINNAGE
Dividends and buybacks
Dividend yield1.2%–
Dividend per share, 12 months$6.30–
Dividend growth a year, past+9.3%over 5 years–
Buyback yield1.9%0.2%
Shareholder yield3.1%0.2%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LIN or NAGE

Didn't find what you were looking for?

Ask us
Which is bigger, Linde or Niagen Bioscience?

By market value, Linde ($243B) is about 1,507.0 times Niagen Bioscience ($161M), at today's prices.

How did LIN and NAGE stock do over the last 10 years?

Since November 17, 2016, LIN's price moved +350.1% and NAGE's -23.0%. With dividends: LIN +431.1% (+18.2% a year), NAGE -23.0% (-2.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, LIN or NAGE?

The dividend yield at today's price is 1.20% for Linde and none for Niagen Bioscience. Over the last twelve months they paid $6.30 and – per share.

What is the P/E of LIN and NAGE?

At today's price, the P/E is 34.6 for LIN and 15.7 for NAGE. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Linde or Niagen Bioscience?

Over the last twelve months, the net margin was 19.3% for Linde and 8.4% for Niagen Bioscience, and the operating margin 25.3% and 3.9%. Revenue was $36.2B and $122M.

Which is the better investment, Linde or Niagen Bioscience?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.